For instance, Sun Pharmaceutical Industries Ltd., India's largest pharmaceutical company by market capitalisation, reported consolidated sales of ₹43,278.9 crore. "FY23 was good for us with consolidated sales growing 12.6%, driven by strong performance across markets, all of which reported double-digit growth. We recorded strong global specialty sales, up 29% to $871 million. The contribution of specialty business has more than doubled from 7% of consolidated revenues in FY18 to 16% in FY23," says Dilip Shanghvi, managing director, Sun Pharma. Shanghvi's net worth grew 19.1%.